Beyond Air has submitted a supplement application for its second-generation LungFit PH 2 device for treating PPHN.

A trial of Insmed’s TPIP suggests daily doses of the inhaled dry powder are well tolerated and may improve blood flow in ...

The first participant has been dosed in a Phase 1 trial testing F230 for the treatment of pulmonary arterial hypertension.

A study of HB-1614 suggests it may improve exercise capacity in adults with pulmonary hypertension associated with ...

Turning 30 is something columnist Anna Jeter never expected to do because of a childhood PH diagnosis. She grapples with the ...

Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one ...

Transplanting gut microbes from healthy rats into a rat model of PAH led to a reduction in disease severity, suggesting a ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Soon after Yutrepia (treprostinil) was approved by the U.S. Food and Drug Administration (FDA) to treat some forms of pulmonary hypertension, the therapy’s maker, Liquidia, scheduled its first ...